Pharmaceutical Executive Daily: SanegeneBio's $1.5 Billion License Agreement with Genentech
Feb 3, 2026
01:52
forum Ask episode
view_agenda Chapters
auto_awesome Transcript
info_circle Episode notes
In today’s Pharmaceutical Executive Daily, a new a is expected to evolve in 2026, the FDA rejects AstraZeneca’s application for a subcutaneous indication of Saphnelo, and SanegeneBio enters a $1 billion global licensing agreement with Genentech focused on RNAi development.
Pharmaceutical Executive